Business Monitor International


Oman Pharmaceuticals & Healthcare Report

Published 13 February 2014

  • 102 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Oman Pharmaceuticals & Healthcare Report

BMI View: This quarter has seen a focus on development and opening of government-funded and private healthcare infrastructure projects aimed at meeting growing domestic demand for healthcare services and positioning the country as a regional medical tourism hub. While the country boasts a number of attractions to gauge foreign drugmakers ' interest , we continue to highlight that Oman's small population and limited per capita spending limits pharmaceutical market growth .

Headline Expenditure Projections

  • Pharmaceuticals: OMR175mn (US$455mn) in 2013 to OMR191mn (US$503mn) in 2014; 9.3% in local currency terms and 10.7% in US dollar terms. Forecast broadly in line with Q114.

  • Healthcare: OMR785mn (US$2.04bn) in 2013 to OMR852mn (US$2.24bn) in 2014; +8.6% in local currency terms and +10.0 in US dollar terms. Forecast broadly in line with Q114.

Risk/Reward Rating

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q214, Oman's Pharmaceutical Risk/Reward Rating (RRR) scores 47.1 out of 100, maintaining its position at 11th in the region.

Key Trends And Developments

January 2014

The Ministry of Health launched the Oman National Stroke Guideline, under the auspices of Dr Ahmed bin Mohammed al Saeedi, Minister of Health, aiming to improve the quality of care received by patients with strokes. The guideline will be circulated to different health institutions in the Sultanate to improve the provision of stroke care services, prevention and improve patient rehabilitation.

The Omani government announced 2014 expenditure (including investment spending) of OMR13.5bn, of which OMR1.3bn will be allocated to the healthcare sector. The budget allocation for healthcare infrastructure projects is estimated at OMR384mn, with the main hospitals planned by the government this year including...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Oman Pharmaceutical Sales, Historical Data And Forecasts, 2010-2018
16
Healthcare Market Forecast
17
Table: Oman Healthcare Expenditure Trends, Historical Data and Forecasts, 2010-2018
18
Table: Oman Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017
18
Table: Oman Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017
19
Prescription Drug Market Forecast
20
Table: Oman Prescription Drug Market Indicators, Historical Data And Forecasts, 2010-2018
21
Patented Drug Market Forecast
22
Table: Oman Patented Drug Market Indicators, Historical Data And Forecasts 2010 - 2018
23
Generic Drug Market Forecast
24
Table: Oman Generic Drug Market Indicators, Historical Data And Forecasts, 2010-2018
25
OTC Medicine Market Forecast
25
Table: Oman Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts, 2010-2018
26
Pharmaceutical Trade Forecast
27
Table: Oman Pharmaceutical Trade Data And Forecasts (US$mn), 2010-2018
28
Table: Oman Pharmaceutical Trade Data And Forecasts (OMRmn), 2010-2018
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Oman - Sectors' Contribution To Overall Gdp, Current Prices
32
Table: Oman - Gas Prices For Industrial Consumers
36
Table: Oman - Economic Activity
40
Industry Risk Reward Ratings
41
Middle East And Africa Risk/Reward Ratings
41
Oman Risk/Reward Ratings
49
Rewards
49
Risks
50
Market Overview
51
Industry Trends And Developments
52
Industry Trends And Developments
52
Epidemiology
52
Communicable Diseases
52
Non-Communicable Diseases
53
Healthcare Sector
54
Public Healthcare Sector Developments
56
Private Healthcare Sector Developments
57
Table: Number Of Health Centres In Oman By Region
59
Table: Number And Type Of Health Institutions In Oman In 2011
60
Healthcare Insurance
60
Telemedicine
61
Medical Tourism
62
Research And Development
63
Clinical Trials
65
Regulatory Development
66
Regulatory Developments
67
Intellectual Property Regime
67
Regional Harmonisation
68
Pricing And Reimbursement Regime
69
Competitive Landscape
73
Domestic Pharmaceutical Industry
73
Foreign Pharmaceutical Industry
74
Pharmaceutical Distribution
75
Company Profile
76
Zynova/Oman Pharmaceutical Products Company
76
National Pharmaceutical Industries (NPI)
79
Novartis
82
GlaxoSmithKline
85
Sanofi
87
Johnson & Johnson
89
Demographic Forecast
91
Demographic Outlook
91
Table: Oman's Population By Age Group, 1990-2020 ('000)
92
Table: Oman's Population By Age Group, 1990-2020 (% of total)
93
Table: Oman's Key Population Ratios, 1990-2020
94
Table: Oman's Rural And Urban Population, 1990-2020
94
Glossary
95
Methodology
97
Pharmaceutical Expenditure Forecast Model
97
Healthcare Expenditure Forecast Model
97
Notes On Methodology
98
Risk/Reward Ratings Methodology
99
Ratings Overview
100
Table: Pharmaceutical Risk/Reward Ratings Indicators
100
Indicator Weightings
101

The Oman Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Oman to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc